GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Shiller PE Ratio

Emmaus Life Sciences (Emmaus Life Sciences) Shiller PE Ratio : (As of May. 31, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emmaus Life Sciences Shiller PE Ratio Historical Data

The historical data trend for Emmaus Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Shiller PE Ratio Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Emmaus Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Emmaus Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Shiller PE Ratio falls into.



Emmaus Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Emmaus Life Sciences's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Emmaus Life Sciences's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Emmaus Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 1.503 98.326 1.985
201403 -12.000 99.695 -15.631
201406 -12.000 100.560 -15.496
201409 -12.000 100.428 -15.517
201412 -12.000 99.070 -15.729
201503 -12.000 99.621 -15.642
201506 -12.000 100.684 -15.477
201509 -15.840 100.392 -20.490
201512 -40.440 99.792 -52.624
201603 -1.680 100.470 -2.171
201606 -15.180 101.688 -19.385
201609 -3.068 101.861 -3.911
201612 -4.140 101.863 -5.278
201703 -3.660 102.862 -4.621
201706 -3.720 103.349 -4.674
201709 -3.696 104.136 -4.609
201712 -3.840 104.011 -4.794
201803 -3.540 105.290 -4.366
201806 -2.760 106.317 -3.371
201809 -1.200 106.507 -1.463
201812 -1.920 105.998 -2.352
201903 -1.620 107.251 -1.962
201906 -1.200 108.070 -1.442
201909 -0.600 108.329 -0.719
201912 0.190 108.420 0.228
202003 0.110 108.902 0.131
202006 -0.190 108.767 -0.227
202009 0.110 109.815 0.130
202012 0.000 109.897 0.000
202103 -0.170 111.754 -0.198
202106 0.050 114.631 0.057
202109 -0.060 115.734 -0.067
202112 -0.140 117.630 -0.155
202203 -0.030 121.301 -0.032
202206 -0.180 125.017 -0.187
202209 -0.010 125.227 -0.010
202212 0.010 125.222 0.010
202303 -0.070 127.348 -0.071
202306 -0.030 128.729 -0.030
202309 0.000 129.860 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emmaus Life Sciences  (OTCPK:EMMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Emmaus Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501